COST Action bridges the gap in cancer immunotherapy research

Cancer is still a leading cause of death worldwide. Globally, there were an estimated 20 million new cases of cancer and 10 million deaths.

Analyzing process of evolution and adaptation through acquiring new mutations

The influenza (flu) virus is constantly undergoing a process of evolution and adaptation through acquiring new mutations.

July 29, 2023

Ligand agrees to acquire APEIRON Biologics for $100m

QARZIBA is indicated to treat high-risk neuroblastoma in patients aged 12 months and above. Credit: Kateryna Kon/Shutterstock. Ligand Pharmaceuticals has announced a definitive agreement for

July 9, 2024

Breakthrough in Malaria detection: new FREM platform delivers 98% accuracy for rapid screening and genotyping

The Flexible, Robust, Equipment-free Microfluidic (FREM) platform for malaria screening and Plasmodium species genotyping.

December 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.